Phase 1/2 Study of IMC-R117C in Selected Advanced Cancers
← catalyst calendarNCT06840119 · readout in 103 d
Sponsored by Immunocore Ltd (industry) · IMCR — their whole pipeline →.
Phase
Phase 1/2
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
600estimated
Sites
13
Countries
Australia, Belgium, Germany +3
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-01-10 | actual | When the study began enrolling |
| Primary completion | 2026-11-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-11-30 | estimated | The whole study's end, after follow-up |
| First posted | 2025-02-21 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-01-28 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Cancer
- HLA-A*02:01-positive
Interventions
- Drug: IMC-R117C
- Drug: Chemotherapy drug
- Drug: Chemotherapy drug
- Drug: Kinase inhibitor
- Drug: Antiangiogenic Agent
- Drug: Monoclonal antibody
Primary outcomes
what the primary-completion date above is the date OFDose Escalation: Percentage of participants with ≥1 dose-limiting toxicity (DLT)
measured Up to ~24 months
Dose Escalation: Percentage of participants with ≥1 adverse event (AE)
measured Up to ~24 months
Dose Escalation: Percentage of participants with ≥1 serious adverse event (SAE)
measured Up to ~24 months
Dose Escalation: Percentage of participants with significant changes in electrocardiogram (ECG) recordings
measured Up to ~24 months
Dose Escalation: Percentage of participants with significant changes in vital signs
measured Up to ~24 months
Dose Escalation: Percentage of participants with significant changes in laboratory results
measured Up to ~24 months
Dose Escalation: Percentage of participants with a dose interruption, reduction, or discontinuation
measured Up to ~24 months
Expansion: Best Overall Response (BOR) as Determined by RECIST v1.1
measured Up to ~24 months
Permalink · IMCR's whole pipeline · Catalyst calendar · Every registered study · What changed